ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Information for professionals for Sodipryl® retard:Sanofi SA
Complete information for professionalsDDDPrint 
Composition.Galenic FormIndication.UsageContra IndicationWarning restrictions.Interactions.Pregnancy
Driving abilityUnwanted effectsOverdoseEffectsPharm.kinetikPreclinicalOther adviceSwissmedic-Nr.
PackagesRegistration ownerLast update of information 
C04AX21 - NaftidrofurylATC-DDD Version 2016. Source: WHO
C - Cardiovascular System

This group comprises substances used for the treatment of cardiovascular conditions.
Drugs used for the treatment of hypertension are classified in C02 - Antihypertensives, C03 - Diuretics, C07 - Beta blocking agents, C08 - Calcium channel blockers, and C09 - Agents acting on the renin-angiotensin system. For the classification of combination products of antihypertensives from different ATC groups, the following ranking should be used, from higher to lower precedence: C09, C07, C08, and C03.

C04 - Peripheral Vasodilators
 
C04A - Peripheral Vasodilators

This group comprises plain and combined preparations used in the treatment of cerebrovascular or peripheral circulatory disorders.
Combinations with Antihypertensives, see C02 - Antihypertensives.
Combinations with vasodilators used in cardiac diseases, see C01DA.

The DDDs are based on the doses used for the treatment of cerebral and peripheral vascular disorders.

C04AX - Other Peripheral Vasodilators

Betahistine, cinnarizine and flunarizine are classified as antivertigo preparations in N07CA.
Papaverine preparations, see A03AD and G04BE.
Prostaglandin analogues used for pulmonary arterial hypertension or arteriosclerosis obliterans are classified in B01AC.

C04AX21 - Naftidrofuryl
DoseRoute of administrationNote
 O 
2025 ©ywesee GmbH
Settings | Help | FAQ | Login | Contact | Home